Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

General Inception Launches Igniter Europe with the support of leading institutions and venture capital firms


News provided by

General Inception

Apr 29, 2024, 23:00 ET

Share this article

Share toX

Share this article

Share toX

General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, developing novel therapeutics and leveraging disruptive technology platforms.

PALO ALTO, Calif. and LYON, France, April 29, 2024 /PRNewswire-PRWeb/ -- General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel therapeutics and disruptive technology platforms that enable accelerated drug development with data analytics solutions leveraging patients' data and clinical insights early on in the phase of drug development.

Since its establishment in the United States in 2020, General Inception has co-founded over 35 companies across three divisions: (1) Therapeutics, (2) Engineered Biology, and (3) Life Science Tools & Diagnostics. The company works closely with renowned researchers and institutions to facilitate the inception and acceleration of startups. With the assistance of more than 50 staff and entrepreneurs in residence, General Inception brings in critical industry expertise and financial resources to address the fundamental challenges associated with the building of future market leaders. The team operates daily on both sides of the Atlantic to streamline the development of breakthrough solutions for the healthcare industry.

Igniter Europe will continue this mission in Europe, leveraging the unique ecosystem available regionally for startups with the financial support of France 2030's French Tech Accélération 2 fund, managed on behalf of the French government by Bpifrance, KU Leuven, and Paladin Capital Group as initial investors and strategic partners. Venkat Reddy and François Valencony will co-manage this industrial holding, bringing together more than 50 years of consolidated experience in the pharmaceutical and life sciences industry.

Igniter Europe is operational and already supports five innovative companies:

- Abbelight provides hardware and software solutions for Super-Resolution Microscopy to leading research centers, biotechnology and pharmaceutical companies, based on more than 10 years of research conducted at ISMO (Paris Saclay University) and Langevin Institute (ESPCI). The company is currently expanding its product offering and also commercially in North America and Asia.

- Ennovate Pharma was recently launched with the aim of developing innovative treatments for patients who are non-responders or refractory to current standard of care for autoimmune and inflammatory diseases.The company utilizes clinical data and advanced data analytics capabilities to bring more effective medicines to patients.

- GauDDi is an innovative small molecule drug discovery company targeting RNA modifications in immune cells for the treatment of immune-mediated diseases. GauDDi was launched in close collaboration with Pharmacelera, a Barcelona-based software company that specializes in computational chemistry with the use of quantum mechanics algorithms, machine learning, and high-performance computing.

- Nickl Therapeutics was founded in Grand-Est region, France in 2023 with a focus on developing next-generation NK cell and innate lymphoid cell therapeutics for oncology and auto-immune disease. By utilizing highly innovative macrocyclic multi-specific cell engagers, Nickl Therapeutics aims to redirect the cytotoxic capabilities of NK cells for the precision killing of disease mediating cells across a number of therapeutic settings. The initial focus is on the activation of the innate immune system within the microenvironment of solid tumors to enhance cancer cell killing.

- Tavira Therapeutics is developing a modular next-generation AAV capsid platform, with the goal of enhancing tissue-specific transgene delivery for gene therapy. The modularity afforded by the Tavira platform should not only accelerate the development of novel therapies, but also streamline AAV vector manufacturing. By enhancing specificity and reducing immunogenicity, the platform furthermore addresses toxicities associated with AAV-based gene therapy. Tavira is leveraging the cutting-edge AAV gene therapy research and development capabilities of the University of Leuven.

"We thank our existing and new investors, who help us accelerate our expansion in Europe. We believe we can add tremendous value to the European innovation ecosystem, offering access to our industry expertise, international network, and financing capabilities," said Paul Conley, CEO and Co-founder of General Inception.

"We are exceptionally proud of the executives who have joined us over the last 18 months to expand our footprint on both sides of the Atlantic. The diversity, quality and commitment of our team will allow us to build differentiated companies and products in a capital efficient manner," said François Valencony, Chief Business Officer and co-manager of Igniter Europe.

"We are thrilled to offer a platform to innovators who can utilize their scientific expertise to create economic value. We strongly believe that our approach to founding and managing companies, in different innovation corridors throughout Europe, will lead to high-impact projects and contribute to a more efficient and accessible healthcare system," stated Venkat Reddy, Chief Scientific Officer and co-manager of Igniter Europe.

"Igniter Europe's approach in the field of company creation and expansion, in close collaboration with General Inception, is quite original. Thanks to an experienced team and privileged access to major research institutions, this partnership should enable the emergence of leading industrial companies in France over the medium term, to which Bpifrance is delighted to contribute on behalf of the French government," says Pierre Gillet, Investment Director of Bpifrance's French Tech Acceleration fund.

"Our support is based on more than 15 years' experience with the team as deeptech venture capital investors and a shared conviction in the value of their mission. Paladin is strongly committed to advancing digital biology and biosecurity, and we are excited by the potential of Europe's research base in these areas of fundamental value to society," added Mourad Yesayan, Managing Director, Paladin Capital Group.

Media Contact

Elodie Dormes, General Inception, 1 1234567, [email protected], www.generalinception.com 

SOURCE General Inception

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.